Taken together, these data demonstrated that combining metformin with PD-L1 blocking therapeutic antibodies enhanced CTLs efficacy against sunitinib-resistant ccRCC cell lines using a co-culture in-vitro model. Here, CD274 is linked to nonpapillary renal cell carcinoma.